{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Richards AR"],"funding":["NCI NIH HHS","NIH","NIH HHS"],"pagination":["24"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12879400"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(1)"],"pubmed_abstract":["Background
Protein EpiScores are a novel class of DNA methylation (DNAm)-based metrics proposed to measure peripheral immune system characteristics. Although Protein EpiScores have been associated with chronic disease risk, their relationship with colorectal cancer (CRC) survival has not been investigated.Methods
We generated new genome-wide DNAm data on pre-treatment whole blood samples from a case-control sample of 136 newly diagnosed CRC patients nested in the ColoCare Study and calculated 107 Protein EpiScores using the developer's algorithm. Over a median follow-up of 7.3 years (range: 0.3-13.8 years), 35 (26%) patients experienced disease recurrence, and 47 (35%) died. Protein EpiScore associations with disease-free and overall survival were tested using Cox regressio"],"journal":["Clinical epigenetics"],"pubmed_title":["Blood DNA methylation-predicted plasma protein levels and colorectal cancer survival."],"pmcid":["PMC12879400"],"funding_grant_id":["P30-CA076292","P30 CA076292"],"pubmed_authors":["Dowling BI","Toriola AT","Gigic B","Kresovich JK","Shibata D","Siegel EM","Jean-Baptiste E","Gomez MF","Stewart PA","Figueiredo JC","Li CI","Richards AR","Ulrich CM","Byrd DA"],"additional_accession":[]},"is_claimable":false,"name":"Blood DNA methylation-predicted plasma protein levels and colorectal cancer survival.","description":"Background
Protein EpiScores are a novel class of DNA methylation (DNAm)-based metrics proposed to measure peripheral immune system characteristics. Although Protein EpiScores have been associated with chronic disease risk, their relationship with colorectal cancer (CRC) survival has not been investigated.Methods
We generated new genome-wide DNAm data on pre-treatment whole blood samples from a case-control sample of 136 newly diagnosed CRC patients nested in the ColoCare Study and calculated 107 Protein EpiScores using the developer's algorithm. Over a median follow-up of 7.3 years (range: 0.3-13.8 years), 35 (26%) patients experienced disease recurrence, and 47 (35%) died. Protein EpiScore associations with disease-free and overall survival were tested using Cox regressio","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-15T13:17:21.172Z","creation":"2026-07-05T03:08:20.328Z"},"accession":"S-EPMC12879400","cross_references":{"pubmed":["41622289"],"doi":["10.1186/s13148-026-02059-3"]}}